Gibson Teresa Bernard, McLaughlin Catherine G, Smith Dean G
Thomson-Reuters, Ann Arbor, MI, USA.
Adv Health Econ Health Serv Res. 2010;22:195-219. doi: 10.1108/s0731-2199(2010)0000022012.
The purpose of this study is to estimate the own- and cross-price elasticity of brand-name outpatient prescription drug cost-sharing for maintenance medications and to estimate the effects of changes in the price differential between generic and brand-name prescription drugs.
METHODOLOGY/APPROACH: We first review the literature on the effects of an increase in brand-name drug patient cost-sharing. In addition, we analyze two examples of utilization patterns in filling behavior associated with an increase in brand-name cost-sharing for patients in employer-sponsored health plans with chronic illness.
We found that the own-price elasticity of demand for brand-name prescription drugs was inelastic. However, the cross-price elasticity was not consistent in sign, and utilization patterns for generic prescription fills did not always increase after a rise in brand-name cost-sharing.
The empirical examples are limited to the experience of patients with employer-sponsored health insurance.
The common practice of increasing brand-name prescription drug patient cost-sharing to increase consumption of generic drugs may not always result in higher generic medication use. Higher brand-name drug cost-sharing levels may result in discontinuation of chronic therapies, instead of therapeutic switching.
ORIGINALITY/VALUE OF CHAPTER: The value of this chapter is its singular focus on the effects of higher brand-name drug cost-sharing through a synthesis of the literature examining the own- and cross-price elasticity of demand for brand-name medications and two empirical examples of the effects of changes in brand-name cost-sharing.
本研究旨在估计品牌门诊处方药维持用药费用分担的自身价格弹性和交叉价格弹性,并估计非专利药与品牌处方药价格差异变化的影响。
方法/途径:我们首先回顾了关于品牌药患者费用分担增加影响的文献。此外,我们分析了两个与患有慢性病的雇主赞助健康计划患者的品牌药费用分担增加相关的配药行为使用模式示例。
我们发现品牌处方药需求的自身价格弹性缺乏弹性。然而,交叉价格弹性的符号并不一致,并且在品牌药费用分担增加后,非专利药的配药使用模式并不总是增加。
实证示例仅限于雇主赞助健康保险患者的经验。
增加品牌处方药患者费用分担以增加非专利药消费的常见做法可能并不总是导致更高的非专利药使用量。更高的品牌药费用分担水平可能导致慢性治疗中断,而不是治疗转换。
本章的原创性/价值:本章的价值在于通过综合研究品牌药需求的自身价格弹性和交叉价格弹性的文献以及品牌药费用分担变化影响的两个实证示例,单独关注更高品牌药费用分担的影响。